Profil
Ms. Amy Conrad is a Founder & Chief Executive Officer at Juniper Point, Inc. and a Head-Investor Relations at Tyra Biosciences, Inc. Ms. Conrad was previously employed as a Head-Investor Relations by Anadys Pharmaceuticals, Inc., a Head-Investor Relations by Bionano Genomics, Inc., and an Investor Relations & Media Contact by Regulus Therapeutics, Inc.
Aktive Positionen von Amy Conrad
| Unternehmen | Position | Beginn |
|---|---|---|
| TYRA BIOSCIENCES, INC. | Investor Relations Kontakt | - |
| Juniper Point, Inc. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Amy Conrad
| Unternehmen | Position | Ende |
|---|---|---|
| REGULUS THERAPEUTICS INC. | Investor Relations Kontakt | 01.01.2016 |
| BIONANO GENOMICS, INC. | Investor Relations Kontakt | - |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Investor Relations Kontakt | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BIONANO GENOMICS, INC. | Health Technology |
| REGULUS THERAPEUTICS INC. | Health Technology |
| TYRA BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Anadys Pharmaceuticals, Inc.
Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Health Technology |
| Juniper Point, Inc. |
